Back to ranking
#19USNASDAQ

HRMY

Harmony Biosciences Holdings, Inc.

$36.84USD

Data as of 2026-07-21

Fair value$57.64
Target$83.08
Loss chance20%Low

Company attributes

SizeMid cap
SectorHealth Care
Dividend
TypeCommon stock

Price

Interactive 5-year price history chart for HRMY. Latest close $36.84.

Loading price history…

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=166)
  • Quality
    Profit margins & asset efficiency
    75
    Exceptional
    Health Care median (n=166) 50
  • Value
    Price vs fundamentals
    81
    Exceptional
    Health Care median (n=166) 52
  • Growth
    Revenue & earnings trajectory
    65
    Strong
    Health Care median (n=166) 50
  • Momentum
    Recent price strength
    42
    Average
    Health Care median (n=166) 49
  • Health
    Balance sheet & solvency
    88
    Exceptional
    Health Care median (n=166) 57
  • Profitability
    ROE, ROA, ROIC
    80
    Exceptional
    Health Care median (n=166) 48
  • Technical
    Trend & volatility signals
    51
    Average
    Health Care median (n=166) 56
  • Risk
    Volatility & drawdown profile
    35
    Weak
    Health Care median (n=166) 46
025405570100
Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Recent regulatory events

  • Going-concern disclosure (10-K)Annotate

Risk Summary

Low
Manipulation index
3/100
Composite penalty: 0.30 pts (informational; rank uses raw composite)
Fired components (2)
  • Restatement history (10-K/A, 5y)[restatement_history]
  • Beneish M-score warning band[beneish_high]

Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.

Fair price check

6 different valuation methods each estimate what HRMYshould be worth, then we compare to today's price.

Looks undervalued
Models suggest HRMY is trading below fair value
Today's price
$36.84
Median fair price
$57.64
+56% vs today's price
Of 6 methods:4 say cheap2 say pricey
  • P/B multiplesUndervalued
    thinks it's a bargainestimates $83.08, about 126% above today
  • EV/EBITDAUndervalued
    thinks it's a bargainestimates $81.96, about 122% above today
  • P/E multiplesUndervalued
    thinks it's a bargainestimates $59.37, about 61% above today
  • DCF (2-stage)Undervalued
    thinks it's a bargainestimates $55.92, about 52% above today
  • Graham (defensive)Overvalued
    thinks it's expensiveestimates $28.06, about 24% below today
  • Residual IncomeOvervalued
    thinks it's expensiveestimates $24.05, about 35% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair
$57.64
Margin of safety(vs fair value)
+36.1%
Max (ex-outliers)
$83.08
Tangible BVPS
$14.28
  • Beneish M-score (warning band)
  • Restatement history

Median of all applicable methods (current price $36.84). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

MetricValue
Market cap$2.13B
Revenue (TTM)$899.11M
Net income (TTM)$145.62M
Operating cash flow (TTM)$341.97M
CapEx (TTM)$310.00K
Free cash flow (TTM)CFO − CapEx$341.66M
Total assets$1.27B
Total liabilities$361.48M
Stockholders' equity$910.35M
Cash & equivalents$589.40M
Shares outstanding57.89M
EPS (basic)$2.52
EPS (diluted)$2.52
P/E ratio (TTM)14.65

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date
2026-05-07
Latest period end
2026-05-05
Filing lag
75 days
Missing metrics
2(dividends_paid, goodwill)

Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.